Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.47 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.47 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.47 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 6/20 | 0.44 |
| ▸ | CTSK | P43235 | 5/20 | 0.44 |
| ▸ | ACACB | O00763 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL255695 | 0.86 | ACACB (0.43) | CTSSCTSKACACBPTPN11SYK | |
| SCHEMBL12321525 | 0.86 | CTSS (0.44) | CTSSCTSKMEN1KMT2AADRB2 | |
| SCHEMBL6028072 | 0.85 | CTSS (0.46) | CTSSCTSKCTSLCTSB | |
| SCHEMBL12954734 | 0.85 | MEN1 (0.45) | CTSSCTSKACACBMEN1KMT2A | |
| SCHEMBL30771319 | 0.84 | CTSS (0.45) | CTSSCTSKMEN1KMT2AADRB2 | |
| SCHEMBL31389102 | 0.83 | CTSS (0.42) | CTSSCTSKMEN1KMT2AADRB2 | |
| SCHEMBL29672438 | 0.83 | CTSS (0.44) | CTSSCTSKMEN1KMT2AADRB2 | |
| SCHEMBL16935724 | 0.83 | CTSS (0.42) | CTSSCTSKMEN1KMT2AADRB2 | |
| SCHEMBL12817338 | 0.83 | ACHE (0.44) | GRIA4CTSSCTSKACACBMEN1 | |
| SCHEMBL16063356 | 0.82 | ACACB (0.46) | ACACBPTPN11SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230137-A1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS INC (US) | 2025-07-17 | — | — | US | disclosed |
| EP-3752497-B1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS INC (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-112218857-B | P300/CBP HAT inhibitors and methods of use thereof | 星座制药公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20220331304-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | CONSTELLATION PHARMACEUTICALS, INC. | 2022-10-20 | — | — | US | disclosed |
| US-11414384-B2 | P300/CBP hat inhibitors | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| EP-3752250-B1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS INC (US) | 2022-08-03 | — | — | EP | disclosed |
| EP-4003342-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | Constellation Pharmaceuticals, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| US-20220135538-A1 | P300/CBP HAT INHIBITORS AND METHODS FOR THEIR USE | CONSTELLATION PHARMACEUTICALS, INC. | 2022-05-05 | — | — | US | disclosed |
| CN-112218857-A | P300/CBP HAT inhibitors and methods of use thereof | 星座制药公司 | 2021-01-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11414384-B2 | P300/CBP hat inhibitors | EP300, HDAC1, KAT2A | GRIA1 1615/4885GRIA2 2005/4885GRIA3 1981/4885 |
| US-20220331304-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | CLN6, ACHE, NLN | GRIA1 468/4885GRIA2 241/4885GRIA3 237/4885 |
| US-20220135538-A1 | P300/CBP HAT INHIBITORS AND METHODS FOR THEIR USE | EP300, KAT2A, HDAC1 | GRIA1 1773/4885GRIA2 1775/4885GRIA3 1583/4885 |
| US-20250230137-A1 | P300/CBP HAT INHIBITORS | EP300, HDAC1, KAT2A | GRIA1 1615/4885GRIA2 2005/4885GRIA3 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.